Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

QLT Divests U.S. Business, Retains Wet AMD Treatment Visudyne

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Following a strategic review of its assets, Canadian company divests its only other marketed product, prostate cancer drug Eligard, and lays off 115 employees.

You may also be interested in...



Medical Device Market & Industry Briefs, August 2012

Brief summaries of recent medtech market and industry developments. This month we cover continuing pressures on the DES and ICD markets, update Edwards’ efforts to roll out its Sapien device for TAVR, and report on QLT’s decision to sell its punctal plug technology.

Retaane Fails Again In Macular Degeneration

Alcon halts program after large risk-reduction trial disappoints.

Retaane Fails Again In Macular Degeneration

Alcon halts program after large risk-reduction trial disappoints.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

BrainStorm’s NurOwn: Cell Therapy Lacks Substantial Evidence Of Efficacy In ALS, US FDA Says

Gene And Cell Therapy Clinical Holds Decline While Those For Drugs Hit 12-Year High

Takeda Pens Mid-Trial Settlement To Dismiss US Colcrys Antitrust Suit

Yet Another Bad Day For PBMs On Capitol Hill

See All
UsernamePublicRestriction

Register

PS066743

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By